Our findings suggest that the systemic immunomodulatory properties of MCP-1, coupled with its ability to modify skeletal muscle cell function directly, could make MCP-1 an attractive therapeutic target in sepsis patients, especially in the setting of respiratory muscle dysfunction and ventilatory failure. Here, CCL2 is linked to Sepsis.